{"name":"MeiraGTx, LLC","slug":"meiragtx-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AAV2hAQP1","genericName":"AAV2hAQP1","slug":"aav2haqp1","indication":"Leber congenital amaurosis 10 (LCA10)","status":"phase_1"}]}],"pipeline":[{"name":"AAV2hAQP1","genericName":"AAV2hAQP1","slug":"aav2haqp1","phase":"phase_1","mechanism":"AAV2-mediated gene therapy targeting aquaporin-1","indications":["Leber congenital amaurosis 10 (LCA10)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQQUpuR0FNUDdQVmlWTVI2TDd3a0k1dXMzMndLVUJVVTVPNTFDME9HTDE2WE9HTG9sRGZoczF0SjNtbnk5VEtJUDVSWi1oMVZzMGlHVEJfbDV2aC1kVDJsZnpqS3JUQm4weVVMMjRzYmpwd2k0eUZUM1VjLURIVi1hamd1R0VBUzNncWpLSGFnbDhnV2NOa004R3czaFBuODJSX19ibUJkS05zckZhVVE?oc=5","date":"2025-11-10","type":"deal","source":"fiercebiotech.com","summary":"Lilly bags eye-catching retinal disease gene therapy from MeiraGTx in $475M deal - fiercebiotech.com","headline":"Lilly bags eye-catching retinal disease gene therapy from MeiraGTx in $475M deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-22","type":"pipeline","source":"simplywall.st","summary":"MeiraGTx Holdings (NASDAQ:MGTX) Is Making Moderate Use Of Debt - simplywall.st","headline":"MeiraGTx Holdings (NASDAQ:MGTX) Is Making Moderate Use Of Debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZ0tCNGRmUzhqd3h5S19UMzJSRmtDSXNwdHVFSUlZVHA2MVBibFhkeTNyZ3Bvdm1LekNhSjRTdEZnZVphWTdsb0Vma3BCck53bUdPMVN5VGdHaWQ0b1NBTkx1QUJJQTQ5cUxpdm1oUEJyS0RLWDZmR2NWdDhYQ1EzR3FNaVZreTVvd3psd1dSQjN4YmJIalRjM2VVd3NuRlZuOEZLVFRtOVhrTk9PZlZSNjhLbV96d05kN2hF?oc=5","date":"2025-05-05","type":"trial","source":"fiercebiotech.com","summary":"J&J gene therapy fails to improve visual navigation in late-stage rare eye disease trial - fiercebiotech.com","headline":"J&J gene therapy fails to improve visual navigation in late-stage rare eye disease trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNdmp5OUVwd2FIRERDeEhZcDBCbzU0NFdHS25TQWdfZnhSaVFfbW9YUkI5YTFuYUt5YnpjczZrZ0l1Sng3dDllNlJKS0FpZjEzUWxFVzdyT1Fpc1YzLXJZWWh2S1ZfOWp4aDhZWGNSMndxN2Eydmg1aTRjc1kxY1p6NERFWUU4aFNOczFOeWtKWHJfUERPeU0wdldISmo4cnZHdmZ2M24xSUQzVTNUZTVNTVhYOA?oc=5","date":"2025-03-13","type":"trial","source":"fiercebiotech.com","summary":"Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond - fiercebiotech.com","headline":"Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaEJ5M2lCa1RfLTY4STBTR1NjREZjWlRyM2IxTzVZSDlUZUxLZGlKYjJ6N0h4U1hTR2NuYXl4anF3N24yUDdRdGRVdUtGc3pMU1F0ZUN2eHFSY3ZmWGFRaE9MQ2pXZDZ1MVNQY2lfRmY5clV3VWRGR2lWX01Yck1qMURTNE1NUElGRzNQVmVSd3JZRTAzSVczeHphYXVGZXJQSUQ0cG1oRmIzb3NlYWx3R2NKNVRaZFU5Yl9yaTZyWHpfWjg?oc=5","date":"2025-02-21","type":"regulatory","source":"fiercebiotech.com","summary":"MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerated approval - fiercebiotech.com","headline":"MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerated approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOYWNkYm1Zd085M0lwc3VBVDJuX0ZJS1RJTUhEU1FwTmJYTDRzUXdMNll4OHRKeVdaQi1tUTJjWEtqX21EaXkxanRrcUtkUk9laXFTOG43d29YOTFoN0Z0eVQwSGZLNmxkSnVRODJXbnJHVHYxcXNsVTRKSE53WmctWUhuNzZraWNPSUtRMW1sQzRCcmNw?oc=5","date":"2023-12-21","type":"regulatory","source":"fiercebiotech.com","summary":"MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M - fiercebiotech.com","headline":"MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxNU3dhbDBTTHpGMktyNmQxZGtUdUFXYm5nT3I3VFlQTF9TUEh3SHdPX1lhTlR3blVRdDZxYzZ1RXZlOHVNVWt3MnJxRzlMQmVjM2FwT3RzMU43akxXc1czQmE5UGtQQ09VbUM4cjN4T3RhdnNTYlNjTVJ0UE9oSGVNSHQ1UWJteTZfTnBuSF9QdXE0ZWNKNXN1Mm90MWhHSUFsaWc3dEItNkZKeWw4b1Fla0xiV0RaR0VvMEJoek5HSU5EdGhqRVBaQnlUOHR5ZVE2XzF5ZkpjSjZMeVY3dkd4a0lOR3MxV3JwbW4yekdFUFNJN2drNkZocC1pNlpETVhLdzFRcVZiejRtQmNlOHNmNGZFTUVZcndyQzJBYQ?oc=5","date":"2023-04-21","type":"pipeline","source":"prnewswire.com","summary":"Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting - prnewswire.com","headline":"Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPWjhTeGRMS3NJQjRBSjNQY0J0VzJEbWhqWk5hVVFodjJHaFg1RjZQTGVVZU9KVTNtMmZJakZlYmZMMUdqa0ZBc0s5bm5uWTZwTzNYck1XTFpTRG42R2NDUkRTSzAwTGM1aURaZ3FUTkQ5RnJlRVgyb1NLNklERFdoY0lGUEFfWXNEMnQyWWU0bkFYeWZ4N0JQMHp2VWdfRU0zX0Jja0ZYcFhXR1BKR3RkS1lXN3djbVZP?oc=5","date":"2022-09-19","type":"pipeline","source":"Fierce Pharma","summary":"MeiraGTx unveils Ireland's first site capable of commercial-stage gene therapy manufacturing - Fierce Pharma","headline":"MeiraGTx unveils Ireland's first site capable of commercial-stage gene therapy manufacturing","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}